Debt-free Balance SheetA debt-free balance sheet materially reduces refinancing and interest-rate risk, granting Sprint flexibility to fund R&D, pursue partnerships, or time licensing negotiations without immediate capital market pressure. This durability supports long-term project advancement and negotiating leverage with partners.

2025 Profitability And Revenue Step-changeThe 2025 step-change to material revenue and positive net income demonstrates the company’s ability to convert discovery-stage assets into partnerable, monetizable outcomes. Sustained ability to generate milestone/license revenue strengthens cash generation potential and partner credibility over coming cycles.

Partnering/licensing Business ModelA licensing-focused model is capital-light and scalable: once programs reach partner-readiness, future upside comes via milestone and royalty streams rather than heavy internal clinical spend. This structural model aligns incentives with partners and can preserve capital while delivering asymmetric upside from successful deals.

Bears Say

Lumpy Cash Flows And Uneven Cash GenerationBiotech milestone and licensing receipts are inherently lumpy; Sprint’s cash flow swung from negative to strongly positive in 2025. That irregularity makes multi-period planning and stable R&D funding harder, raising the probability of periodic financing needs or delayed program advancement tied to payment timing.

Historical Instability In Equity/capital BasePrior very low equity levels indicate sensitivity to funding and burn; despite recent improvement, past capital instability implies the company may need intermittent external financing. That can dilute shareholders or constrain strategic choices if future milestones or partner deals are delayed.

Revenue Dependent On Partner ProgressSprint’s earnings model relies on external partners progressing licensed assets through development and commercialization. That creates structural revenue exposure to third-party clinical, regulatory and commercial execution—factors outside Sprint’s control that can delay or reduce milestone and royalty income over the medium term.

5JA1 FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was €0.02 and its highest was €0.19 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is €18.85M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 58 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported €0.1 earnings per share for the quarter, beating the consensus estimate of N/A by €0.1.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of €0.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.614%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in DE:5JA1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.